Metastatic Melanoma

Oncology·MeSH: Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

28 drugs in development·12 companies·30 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
braftovi	ARRAY BIOPHARMA INC (ARRY)
mektovi	ARRAY BIOPHARMA INC (ARRY)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
proleukin	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Phase 3(5)

Drug	Company
administration of lymphodepletion	GH Research PLC (GHRS)
adoptive cell therapy with til	GH Research PLC (GHRS)
dabrafenib	Novartis AG (NVS)
high dose il-2	GH Research PLC (GHRS)
Lymphodepletion	Filana Therapeutics Inc. (FLNA)

Phase 2(10)

Drug	Company
Elraglusib Oral Tablet	ACTUATE THERAPEUTICS, INC. (ACTU)
Encorafenib	Novartis AG (NVS)
fludarabine as part of lymphodepletion	GH Research PLC (GHRS)
Lifileucel	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
LN-145-S1	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Lymphodepletion	ENANTA PHARMACEUTICALS INC (ENTA)
Pemetrexed	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
tavo	ONCOSEC MEDICAL INC (ONCS)
Vemurafenib	Filana Therapeutics Inc. (FLNA)
Vemurafenib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(2)

Drug	Company
neo-pv-01	Neon Therapeutics, Inc. (NTGN)
tbio-4101	GH Research PLC (GHRS)

Preclinical(1)

Drug	Company
ca4p	Oncotelic Therapeutics, Inc. (OTLC)

Phase 1/Phase 2(3)

Drug	Company
part 1	GH Research PLC (GHRS)
part 2	GH Research PLC (GHRS)
phase 1b	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Phase 4(3)

BioSniper tracks 28 drugs in development for Metastatic Melanoma across 12 companies.

There are 30 clinical trials targeting Metastatic Melanoma tracked by BioSniper.

The estimated prevalence of Metastatic Melanoma is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.